Leqembi Wins Full Approval and Market Edge With Medicare Coverage
Eisai’s antiamyloid antibody Leqembi (lecanemab-irmb) has now gained full FDA approval — and the market advantage of full CMS coverage.
Source: Drug Industry Daily
Eisai’s antiamyloid antibody Leqembi (lecanemab-irmb) has now gained full FDA approval — and the market advantage of full CMS coverage.
Source: Drug Industry Daily